Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Mar;28(3):164–170. doi: 10.1007/BF00204984

Tumor cytotoxicity of human monocyte membrane-bound interleukin-1α induced by synergistic actions of interferon-γ and synthetic acyltripeptide, FK-565

Noriaki Inamura 1, Saburo Sone 1,✉, Akio Okubo 1, Eiji Kunishige 1, Mie Nakanishi 1, Takeshi Ogura 1
PMCID: PMC11038355  PMID: 2493987

Abstract

Human blood monocytes were isolated by counter-flow centrifugal elutriation from healthy donors and these noncytotoxic monocytes were rendered tumoricidal to allogeneic melanoma (A375) cells by activation with a synthetic acyltripeptide (FK-565), as assessed by measuring release of [125I]iododeoxyuridine in 72 h. When monocytes were treated with FK-565 for 16 h, and then fixed with paraformaldehyde, they showed cytotoxicity to A375 melanoma cells. The fixed-monocyte-mediated cytotoxicity to A375 cells was induced by the synergistic actions of FK-565 and recombinant interferon-γ (rIFN-γ), but not other cytokines [rIFN-αA, rIFN-β, tumor necrosis factor (TNF), interleukin (IL)-2, -3 and -6]. For synergistic activation of monocytes with induction of a membrane-associated antitumor monokine, the monocytes had to be incubated first with rIFN-γ and then with FK-565. FK-565 also acted synergistically with rIFN-γ to stimulate monocytes to produce membrane-associated IL-1 activity, which induced C3H/HeJ thymocyte blastogenesis in response to phytohemagglutinin P. The tumoricidal and thymocytestimulating activities of the fixed monocytes were almost completely inhibited by a specific anti-(IL-1α) antiserum, but not by a specific anti-(IL-1β) antiserum or monoclonal anti-TNF antibody. These results suggest that membrane-associated IL-1α of human blood monocytes can be induced by two activation signals (rIFN-γ then FK-565) at their suboptimal concentrations.

Keywords: Melanoma, Tumor Necrosis Factor, Paraformaldehyde, A375 Cell, Melanoma Cell

Abbreviations

IL

interleukin

IFN

interferon

TNF

tumor necrosis factor

References

  • 1.Bakouche O, Brown DC, Lachman LB. Subcellular localization of human monocyte interleukin 1: evidence for an inactive precursor molecule and a possible mechanism for IL1 release. J Immunol. 1987;138:4249. [PubMed] [Google Scholar]
  • 2.Bakouche O, Ichinose Y, Heicappel R, Fidler IJ, Lachman LB. Plasma membrane-associated tumor necrosis factor: a non-integral membrane protein possibly bound to its own receptors. J Immunol. 1988;140:1142. [PubMed] [Google Scholar]
  • 3.Bakouche O, Lachman LB, Knowles RD, Kleinerman ES (1988) Cytotoxic liposomes: membrane interleukin 1 presented in multilamellar vesicles. J Immunol (in press) [PubMed]
  • 4.Conlon PJ, Grabstein KH, Alpert A, Prickett KS, Hopp TP, Gillis S. Localization of human mononuclear cell inter leukin 1. J Immunol. 1987;139:98. [PubMed] [Google Scholar]
  • 5.Dean RT, Virelizier JL. Interferon as a macrophage-activating factor. I. Enhancement of cytotoxicity by fresh and matured human monocytes in the absence of other soluble signals. Clin Exp Immunol. 1983;51:501. [PMC free article] [PubMed] [Google Scholar]
  • 6.Decker T, Lohmann-Matthes M, Gifford GE. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol. 1987;61:443. [PubMed] [Google Scholar]
  • 7.Dinarello CA. Interleukin 1. Rev Infect Dis. 1985;6:51. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  • 8.Espevik T, Nissen-Mayer J. Tumor necrosis factor-like activity on paraformaldehyde-fixed monocyte monolayers. Immunology. 1987;61:443. [PMC free article] [PubMed] [Google Scholar]
  • 9.Feinman R, Henriksen-DeStefano D, Tsujimoto M, Vilcek J. Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol. 1987;138:635. [PubMed] [Google Scholar]
  • 10.Fidler IJ. Macrophages and metastasis — a biological approach to cancer therapy. Presidental address. Cancer Res. 1985;45:4714. [PubMed] [Google Scholar]
  • 11.Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417. doi: 10.1093/jnci/51.5.1417. [DOI] [PubMed] [Google Scholar]
  • 12.Henmi K, Aratani M, Takeno H, Okada S, Miyazaki Y, Nakaguchi O, Kitaura Y, Hashimoto M. Studies on a new immunoactive peptide, FK-156. 4. Synthesis of FK-156 and its geometric isomer. J Antibiot. 1982;35:130. doi: 10.7164/antibiotics.35.1300. [DOI] [PubMed] [Google Scholar]
  • 13.Hinuma S, Onda H, Naruo K, Ichimori Y, Koyama M, Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun. 1982;109:363. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  • 14.Hurme M. Membrane-associated interleukin 1 is required for the activation of T cells in the anti-CD3 antibody-induced T cell response. J Immunol. 1987;139:1168. [PubMed] [Google Scholar]
  • 15.Inamura N, Nakahara K, Kino T, Gotoh T, Kawamura I, Aoki H, Imanaka H, Sone S. Activation of tumoricidal properties in macrophages and inhibition of experimentally-induced murine metastases by a new synthetic acyltripeptide, FK-565. J Biol Resp Modif. 1985;4:408. [PubMed] [Google Scholar]
  • 16.Jett JR, Mantovani A, Herberman RB. Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol. 1980;54:425. doi: 10.1016/0008-8749(80)90222-1. [DOI] [PubMed] [Google Scholar]
  • 17.Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA. 1985;82:120. doi: 10.1073/pnas.82.4.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kurt-Jones EA, Virgin IV HW, Unanue ER. Relationship of macrophage Ia and membrane IL-1 expression to antigen presentation. J Immunol. 1985;135:3652. [PubMed] [Google Scholar]
  • 19.Kurt-Jones EA, Virgin IV HW, Unanue ER. In vivo and in vitro expression of macrophage membrane interleukin 1 in response to soluble and particulate stimuli. J Immunol. 1986;137:10. [PubMed] [Google Scholar]
  • 20.Lachman LB, Dinarello CA, Llansa ND, Fidler IJ. Natural and recombinant human interleukin 1-β is cytotoxic for human melanoma cells. J Immunol. 1986;136:3098. [PubMed] [Google Scholar]
  • 21.Le J, Prensky W, Yip YK, Chang Z, Hoffman T, Stevenson HC, Balazs I, Sadlik JR, Vilcek J. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol. 1983;131:2821. [PubMed] [Google Scholar]
  • 22.Lovett D, Kozan B, Hadan M, Resch K, Gemsa D. Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol. 1986;136:340. [PubMed] [Google Scholar]
  • 23.March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, Conlon PJ, Hopp TP, Cosman D. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315:641. doi: 10.1038/315641a0. [DOI] [PubMed] [Google Scholar]
  • 24.Mine Y, Yokota Y, Wakai Y, Fukuda S, Nishida M, Gotoh S, Kuwahara S. Immunoactive peptide, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice. J Antibiot. 1983;36:1045. doi: 10.7164/antibiotics.36.1045. [DOI] [PubMed] [Google Scholar]
  • 25.Nishida T, Nishino N, Takano M, Kawai K, Bando K, Masui Y, Nakai S, Hirai Y. cDNA cloning of IL-1α and IL-1β from mRNA of U937 cell line. Biochem Biophys Res Commun. 1987;143:345. doi: 10.1016/0006-291x(87)90671-1. [DOI] [PubMed] [Google Scholar]
  • 26.Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985;135:3962. [PubMed] [Google Scholar]
  • 27.Sone S. Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta. 1986;823:227. doi: 10.1016/0304-419x(86)90004-1. [DOI] [PubMed] [Google Scholar]
  • 28.Sone S, Mutsuura S, Ogawara M, Utsugi T, Tsubura E. Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state. Cancer Immunol Immunother. 1984;18:169. doi: 10.1007/BF00205507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sone S, Tandon P, Utsugi T, Ogawara M, Shimizu E, Nii A, Ogura T. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Int J Cancer. 1986;38:495. doi: 10.1002/ijc.2910380407. [DOI] [PubMed] [Google Scholar]
  • 30.Sone S, Okubo A, Inamura N, Nii A, Ogura T. Synergism of synthetic acyltripeptide and its analogs with recombinant interferon γ for activation of antitumor properties of human blood monocytes. Cancer Immunol Immunother. 1988;27:33. doi: 10.1007/BF00205755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tanaka K, Ishikawa E, Ohmoto Y, Hirai Y. Highly sensitive sandwich enzyme immunoassay for human interleukin 1β (hIL-1β) in urine using affinity-purified anti-hIL-1β Fab'-peroxidase conjugate. Clin Chim Acta. 1987;166:237. doi: 10.1016/0009-8981(87)90426-8. [DOI] [PubMed] [Google Scholar]
  • 32.Tandon P, Utsugi T, Sone S. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide. Cancer Res. 1986;46:5039. [PubMed] [Google Scholar]
  • 33.Utsugi T, Sone S. Comparative analysis of the priming effect of human interferon gamma, alpha and beta on synergism with muramyl dipeptide analog for antitumor expression of human blood monocytes. J Immunol. 1986;136:1117. [PubMed] [Google Scholar]
  • 34.Ziegler-Heitbrock HW, Moler A, Linke RP, Haas JG, Rieber EP, Riethmuller G. Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity. Cancer Res. 1986;46:5947. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES